Journal: Brain : a journal of neurology

Article Title: Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis.

doi: 10.1093/brain/awz301

Figure Lengend Snippet: Figure 4 GZMK but not GZMA expression is a prerequisite of CCR5high lymphocytes’ transcellular diapedesis. (A) Spearman correlation of GZMA/K expression and number of diapedesis events through a HBMEC monolayer by CCR5high CD4 + TEM cells. (B) Left: Representative density plot of GZMK and CCR5 staining of CD4 + TEM T cells. Right: Number of migrated CCR5 CCR5low, CCR5high CD8 + TEM / field of view through a HBMEC monolayer (n = 3) tracked via live cell microscopy, field of view = 1.6 mm2. (C) Left: Representative density plot of GZMK and CD56 staining of NK cells. Right: Number of migrated CD56dim, CD56bright NK cells/field of view through a HBMEC monolayer (n = 6) tracked via live cell microscopy, field of view = 1.6 mm2. (D) Number of migrated CCR5high CD4 + TEM/field of view through a HBMEC monolayer tracked via live cell microscopy after incubation with batimastat (50 mM, n = 6) or JNJ0966 (10 mM; n = 6). (E) Quantification of the percentage of HBMECs expressing ICAM1 after incubation with recombinant human GZMK (250 nM, n = 6) and batimastat (50 mM, n = 3) for min, field of view = 1.6 mm2. (F) Representative immunofluorescence images of in vitro transmigrating CCR5high CD4 + TEM cells (white arrow) through unstimulated HBMECs for the discrimination of trans- (left) paracellular (right) diapedesis. Immunofluorescence staining for VE-Cadherin (green), CD4 (red), and nuclear staining (DAPI, blue). Scale bar = 30 mm. (G) Quantification of the percentage of transcellularly migrating CCR5low, CCR5high CD4 + TEM through unstimulated HBMEC/field of view, (n = 7, field of view = 5 mm2). (H) Exemplary transmission electron microscopic image of in vitro transcellular migration CCR5high TEM cells (depicted in blue) across HBMECs (depicted in red). Endothelial nuclei are indicated by a dashed white line. Scale bar = 1.3 mm. (I) Exemplary confocal microscopic images of in vitro transmigrating CCR5high TEM cells (white arrow) through unstimulated HBMEC. Immunofluorescence staining for GZMK (green), actin (red) and nuclear staining (DAPI, blue). Scale bar = 10 mm.

Article Snippet: If indi- cated, cells were incubated with blocking antibodies against CD49d (natalizumab, Biogen), CD11a (clone: HI111) (BD Biosciences), CD54 (clone: HCD54) (BioLegend), CD102 (clone: CBR-IC2/2) (BioLegend), CCL3 (clone: 93321), CCL4 (clone: 24006) (both R&D Systems), CCL5/ RANTES (clone: 2D5) (BD Biosciences) or chemical antag- onists batimastat (Merck), maraviroc, (Sigma-Aldrich) or JNJ0996 (MedChemExpress).

Techniques: Expressing, Staining, Microscopy, Incubation, Recombinant, In Vitro, Transmission Assay, Migration

Journal: Current medicinal chemistry

Article Title: Nanocarriers for Tracking and Treating Diseases

doi: 10.2174/0929867311320280007

Figure Lengend Snippet: Targeted-NP-Based Therapeutics which Follow Active Targeting

Article Snippet: Solid tumors, Breast cancer SN-38 Phase II/ {"type":"clinical-trial","attrs":{"text":"NCT00951054","term_id":"NCT00951054"}} NCT00951054 Open in a separate window NP-Based Therapeutics which Follow Passive Targeting table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Trade name NP Type Company Targeting Ligand Disease Payload Current Status Clinical Trial No. SGT-53 Liposome SynerGene Therapeutics, Inc. Transferrin single-chain antibody fragment Advanced solid tumors Gene 53 Phase Ib {"type":"clinical-trial","attrs":{"text":"NCT00470613","term_id":"NCT00470613"}} NCT00470613 MBP-426 Liposome Mebiopharm Transferrin Solid tumors and esophagus disorders Oxaliplatin Phase II {"type":"clinical-trial","attrs":{"text":"NCT00355888","term_id":"NCT00355888"}} NCT00355888 , {"type":"clinical-trial","attrs":{"text":"NCT00964080","term_id":"NCT00964080"}} NCT00964080 SEL-068 Polymeric Selecta Biosciences Small molecule Smoking cessation vaccine Nicotine antigen T-helper cell peptide, TLR agonist Phase I {"type":"clinical-trial","attrs":{"text":"NCT01478893","term_id":"NCT01478893"}} NCT01478893 CALAA-01 Polymeric Calando Human Transferrin Solid tumors siRNA Phase Ib {"type":"clinical-trial","attrs":{"text":"NCT00689065","term_id":"NCT00689065"}} NCT00689065 BIND-014 Polymeric Bind Biosciences PSMA peptide Metastatic cancer Docetaxel Phase I {"type":"clinical-trial","attrs":{"text":"NCT01300533","term_id":"NCT01300533"}} NCT01300533 SGT-94 Liposome SynerGene Therapeutics, Inc Anti-transferrin receptor single chain antibody fragment Solid tumors RB94 gene Phase I {"type":"clinical-trial","attrs":{"text":"NCT01517464","term_id":"NCT01517464"}} NCT01517464 Open in a separate window Targeted-NP-Based Therapeutics which Follow Active Targeting Liposomes: Liposomes are biodegradable and essentially non-toxic drug delivery vehicles [ 12 ].

Techniques: